CAM-101 not checked
Cambium Bio Limited · FD hPL 10% vol/vol · FD hPL 30% vol/vol
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Dry Eye Disease, Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes
- Main trialPhase 3
- “Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.”In the company’s words, NCT06903611 on ClinicalTrials.gov
- Other names
- Elate Ocular · FD hPL · FD hPL 10% vol/vol · FD hPL 30% vol/vol
Other drugs for Dry Eye Disease
- DeucravacitinibBristol Myers Squibb · Phase 3
- LicaminlimabOculis · Phase 2/3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- OT202Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3
Coming up1
- 30 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Nov 2027 | Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye | |
| Phase 1/2Completed | 12 Dec 2019 | Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026